PURPOSE: A new universal tool for specific, non-covalent and non-destructive attachment of a recombinant antibody fragment to a polymer-modified adenovirus has been utilised to regulate the tropism of adenoviral gene delivery vector. METHODS: We have prepared a multivalent reactive N-(2-hydroxypropyl)methacrylamide-based copolymer (PHPMA) bearing an α-bungarotoxin-binding peptide (BTXbp). The copolymer was used for covalent surface modification of adenoviral vectors (Ad). The α-bungarotoxin protein (BTX) has a nanomolar binding affinity for BTXbp, allowing non-covalent linkage of BTX fusion proteins. A single chain variable fragment of anti-PSMA antibody bearing BTX (scFv-BTX) binding to the prostate-specific membrane antigen (PSMA) was conjugated with the copolymer-coated adenovirus to enable specific infection of prostate cancer cells via PSMA receptors. RESULTS: As shown by ELISA, the copolymer-coated virus exhibited much reduced binding to anti-Ad antibodies. Infection of PC-3 and LNCaP prostate cancer cells was ∼100-fold less efficient with copolymer-coated Ad than with un-modified Ad. Conjugation of scFv-BTX with Ad-PHPMA-BTXbp led to 5-10-fold restoration of infection in PSMA-positive LNCaP cells. In PSMA-negative PC-3 cells, the conjugation of scFv-BTX with Ad-PHPMA-BTXbp gave no enhancement of infection. CONCLUSIONS: We have shown that the presented Ad-PHPMA-BTXbp/scFv-BTX system can be used as a universal tool for a receptor-specific virotherapy.
PURPOSE: A new universal tool for specific, non-covalent and non-destructive attachment of a recombinant antibody fragment to a polymer-modified adenovirus has been utilised to regulate the tropism of adenoviral gene delivery vector. METHODS: We have prepared a multivalent reactive N-(2-hydroxypropyl)methacrylamide-based copolymer (PHPMA) bearing an α-bungarotoxin-binding peptide (BTXbp). The copolymer was used for covalent surface modification of adenoviral vectors (Ad). The α-bungarotoxin protein (BTX) has a nanomolar binding affinity for BTXbp, allowing non-covalent linkage of BTX fusion proteins. A single chain variable fragment of anti-PSMA antibody bearing BTX (scFv-BTX) binding to the prostate-specific membrane antigen (PSMA) was conjugated with the copolymer-coated adenovirus to enable specific infection of prostate cancer cells via PSMA receptors. RESULTS: As shown by ELISA, the copolymer-coated virus exhibited much reduced binding to anti-Ad antibodies. Infection of PC-3 and LNCaP prostate cancer cells was ∼100-fold less efficient with copolymer-coated Ad than with un-modified Ad. Conjugation of scFv-BTX with Ad-PHPMA-BTXbp led to 5-10-fold restoration of infection in PSMA-positive LNCaP cells. In PSMA-negative PC-3 cells, the conjugation of scFv-BTX with Ad-PHPMA-BTXbp gave no enhancement of infection. CONCLUSIONS: We have shown that the presented Ad-PHPMA-BTXbp/scFv-BTX system can be used as a universal tool for a receptor-specific virotherapy.
Authors: H J de Haard; N van Neer; A Reurs; S E Hufton; R C Roovers; P Henderikx; A P de Bruïne; J W Arends; H R Hoogenboom Journal: J Biol Chem Date: 1999-06-25 Impact factor: 5.157
Authors: Ephraim Katchalski-Katzir; Roni Kasher; Moshe Balass; Tali Scherf; Michal Harel; Mati Fridkin; Joel L Sussman; Sara Fuchs Journal: Biophys Chem Date: 2003 Impact factor: 2.352
Authors: J Nemunaitis; C Cunningham; A Buchanan; A Blackburn; G Edelman; P Maples; G Netto; A Tong; B Randlev; S Olson; D Kirn Journal: Gene Ther Date: 2001-05 Impact factor: 5.250
Authors: M Stevenson; A B H Hale; S J Hale; N K Green; G Black; K D Fisher; K Ulbrich; A Fabra; L W Seymour Journal: Cancer Gene Ther Date: 2007-01-19 Impact factor: 5.987
Authors: Robert C Carlisle; Ying Di; Anna M Cerny; Andreas F-P Sonnen; Robert B Sim; Nicola K Green; Vladimir Subr; Karel Ulbrich; Robert J C Gilbert; Kerry D Fisher; Robert W Finberg; Leonard W Seymour Journal: Blood Date: 2009-01-08 Impact factor: 22.113
Authors: Lynda Coughlan; Raul Alba; Alan L Parker; Angela C Bradshaw; Iain A McNeish; Stuart A Nicklin; Andrew H Baker Journal: Viruses Date: 2010-10-13 Impact factor: 5.818